← 返回专利悬崖列表
奥利司他
Tier C · 观察 / 贸易Orlistat
罗氏
原研
1998
首批上市
-
到期年（公开口径）
无销量数据
峰值销售
化学药
类型
靶点：LIPF
商品名：赛尼可、Zenical、Alli、Xenical
适应症（已批准）：肥胖症
各地区研发/上市状态
美国
批准上市
1999-04-23
欧盟
批准上市
1998-07-29
中国
批准上市
2000-10-31
日本
-
合成路线与中间体5 routes
原研路线 × 1优化路线（非专利）× 4工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线（非专利）」排序。每条路线附本站自绘的路线流程图（中间体 → 原料药）与中间体表（编号 / CAS / 英文名），可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染，未使用任何第三方路线图。
原研Route 1步骤 11 · 总收率 19.20 mg
ORLI-00197-67-6ORLI-002108-94-1ORLI-003153011-57-5ORLI-004153011-59-7ORLI-005153011-60-0ORLI-006—ORLI-007116996-54-4ORLI-008112-29-8ORLI-0091026544-99-9ORLI-01081927-55-1ORLI-011153011-62-2ORLI-012139623-16-8ORLI-013112763-97-0ORLI-01463922-74-7ORLI-015153011-63-3ORLI-016—ORLI-0171026400-12-3ORLI-018114299-20-6ORLI-019114264-05-0ORLI-020104872-06-2ORLI-0216113-61-7API · 奥利司他
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ORLI-001 | 97-67-6在售 | (S)-2-hydroxysuccinic acid |
| ORLI-002 | 108-94-1 | cyclohexanone |
| ORLI-003 | 153011-57-5 | (S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid |
| ORLI-004 | 153011-59-7 | (S)-3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-1,4-dioxaspiro[4.5]decan-2-one |
| ORLI-005 | 153011-60-0 | (S)-methyl 4-((tert-butyldiphenylsilyl)oxy)-2-hydroxybutanoate |
| ORLI-006 | - | - |
| ORLI-007 | 116996-54-4 | (S)-tert-butyl(2-(oxiran-2-yl)ethoxy)diphenylsilane |
| ORLI-008 | 112-29-8 | 1-bromodecane |
| ORLI-009 | 1026544-99-9 | (R)-1-((tert-butyldiphenylsilyl)oxy)tetradecan-3-ol |
| ORLI-010 | 81927-55-1 | benzyl 2,2,2-trichloroacetimidate |
| ORLI-011 | 153011-62-2 | (R)-((3-(benzyloxy)tetradecyl)oxy)(tert-butyl)diphenylsilane |
| ORLI-012 | 139623-16-8 | (R)-3-(benzyloxy)tetradecan-1-ol |
| ORLI-013 | 112763-97-0 | (R)-3-(benzyloxy)tetradecanal |
| ORLI-014 | 63922-74-7 | (E)-trimethyl(non-2-en-1-yl)silane |
| ORLI-015 | 153011-63-3 | (7R,8S,10R)-10-(benzyloxy)-7-vinylhenicosan-8-ol |
| ORLI-016 | - | (((7R,8S,10R)-10-(benzyloxy)-7-vinylhenicosan-8-yl)oxy)(tert-butyl)dimethylsilane |
| ORLI-017 | 1026400-12-3 | (2S,3S,5R)-5-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2-hexylhexadecanoic acid |
| ORLI-018 | 114299-20-6 | (2S,3S,5R)-5-(benzyloxy)-2-hexyl-3-hydroxyhexadecanoic acid |
| ORLI-019 | 114264-05-0 | (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyloxetan-2-one |
| ORLI-020 | 104872-06-2 | (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one |
| ORLI-021 | 6113-61-7 | (S)-2-formamido-4-methylpentanoic acid |
优化Route 2步骤 13 · 总收率 14.70 mg
ORLI-022106-33-2ORLI-0236638-79-5ORLI-024943346-53-0ORLI-02516466-97-0ORLI-0261620409-00-8ORLI-0271620408-77-6ORLI-0281620409-09-7ORLI-0291620408-78-7ORLI-030638-45-9ORLI-0311620409-10-0ORLI-0321620408-79-8ORLI-0331620408-99-2ORLI-0341620408-80-1ORLI-0351620408-98-1ORLI-0361620408-81-2ORLI-037540-63-6ORLI-03868711-40-0ORLI-0392018-66-8ORLI-040108051-94-1ORLI-0412258-42-6API · 奥利司他
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ORLI-022 | 106-33-2 | ethyl dodecanoate |
| ORLI-023 | 6638-79-5在售 | N,O-dimethylhydroxylamine hydrochloride |
| ORLI-024 | 943346-53-0 | N-methoxy-N-methyldodecanamide |
| ORLI-025 | 16466-97-0 | prop-1-yn-1-ylmagnesium bromide |
| ORLI-026 | 1620409-00-8 | pentadec-2-yn-4-one |
| ORLI-027 | 1620408-77-6 | (S)-pentadec-2-yn-4-ol |
| ORLI-028 | 1620409-09-7 | (S)-pentadec-1-yn-4-ol |
| ORLI-029 | 1620408-78-7 | (S)-tert-butyldimethyl(pentadec-1-yn-4-yloxy)silane |
| ORLI-030 | 638-45-9 | 1-iodohexane |
| ORLI-031 | 1620409-10-0 | (S)-tert-butyl(henicos-7-yn-10-yloxy)dimethylsilane |
| ORLI-032 | 1620408-79-8 | (S)-henicos-7-yn-10-ol |
| ORLI-033 | 1620408-99-2 | (S,Z)-henicos-7-en-10-ol |
| ORLI-034 | 1620408-80-1 | (S)-1-((2S,3R)-3-hexyloxiran-2-yl)tridecan-2-ol |
| ORLI-035 | 1620408-98-1 | (2R,3S)-2-hexyl-3-((S)-2-(methoxymethoxy)tridecyl)oxirane |
| ORLI-036 | 1620408-81-2 | (3S,4S)-3-hexyl-4-((S)-2-(methoxymethoxy)tridecyl)oxetan-2-one |
| ORLI-037 | 540-63-6 | ethane-1,2-dithiol |
| ORLI-038 | 68711-40-0 | (3S,4S)-3-hexyl-4-((S)-2-hydroxytridecyl)oxetan-2-one |
| ORLI-039 | 2018-66-8 | (S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanoic acid |
| ORLI-040 | 108051-94-1 | (S)-(S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-(((benzyloxy)carbonyl)amino)-4-methylpentanoate |
| ORLI-041 | 2258-42-6 | acetic formic anhydride |
优化Route 3步骤 17 · 总收率 /
ORLI-020104872-06-2ORLI-0216113-61-7ORLI-042171562-32-6ORLI-043111-64-8ORLI-044296242-29-0ORLI-04514371-10-9ORLI-046296242-28-9ORLI-047296242-40-5ORLI-048296242-30-3ORLI-049296242-41-6ORLI-05016891-99-9ORLI-051296242-31-4ORLI-052296242-32-5ORLI-053296242-33-6ORLI-054296242-34-7ORLI-055296242-42-7ORLI-056296242-35-8ORLI-057296242-36-9ORLI-058296242-37-0ORLI-059296242-38-1ORLI-060296242-39-2API · 奥利司他
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ORLI-020 | 104872-06-2 | (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one |
| ORLI-021 | 6113-61-7 | (S)-2-formamido-4-methylpentanoic acid |
| ORLI-042 | 171562-32-6 | N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-4-methylbenzenesulfonamide |
| ORLI-043 | 111-64-8 | octanoyl chloride |
| ORLI-044 | 296242-29-0 | (1S,2R)-1-(4-methylphenylsulfonamido)-2,3-dihydro-1H-inden-2-yl octanoate |
| ORLI-045 | 14371-10-9 | cinnamaldehyde |
| ORLI-046 | 296242-28-9 | (S)-(1S,2R)-1-(4-methylphenylsulfonamido)-2,3-dihydro-1H-inden-2-yl 2-((S,E)-1-hydroxy-3-phenylallyl)octanoate |
| ORLI-047 | 296242-40-5 | (S)-2-((S,E)-1-hydroxy-3-phenylallyl)octanoic acid |
| ORLI-048 | 296242-30-3 | (2S,5S,6S)-2-(tert-butyl)-5-hexyl-6-((E)-styryl)-1,3-dioxan-4-one |
| ORLI-049 | 296242-41-6 | (2S,4R,5S)-2-(tert-butyl)-5-hexyl-6-oxo-1,3-dioxane-4-carbaldehyde |
| ORLI-050 | 16891-99-9 | 1-nitrododecane |
| ORLI-051 | 296242-31-4 | (2S,5S,6R)-2-(tert-butyl)-5-hexyl-6-((1S)-1-hydroxy-2-nitrotridecyl)-1,3-dioxan-4-one |
| ORLI-052 | 296242-32-5 | (2S,5S,6S)-2-(tert-butyl)-5-hexyl-6-((Z)-2-nitrotridec-1-en-1-yl)-1,3-dioxan-4-one |
| ORLI-053 | 296242-33-6 | (2S,5S,6S)-2-(tert-butyl)-5-hexyl-6-((E)-2-(hydroxyimino)tridecyl)-1,3-dioxan-4-one |
| ORLI-054 | 296242-34-7 | (2S,5S,6S)-2-(tert-butyl)-5-hexyl-6-(2-oxotridecyl)-1,3-dioxan-4-one |
| ORLI-055 | 296242-42-7 | (2S,3S)-2-hexyl-3-hydroxy-5-oxohexadecanoic acid |
| ORLI-056 | 296242-35-8 | (2S,3S)-benzyl 2-hexyl-3-hydroxy-5-oxohexadecanoate |
| ORLI-057 | 296242-36-9 | (2S,3S,5R)-benzyl 2-hexyl-3,5-dihydroxyhexadecanoate |
| ORLI-058 | 296242-37-0 | (2S,3S,5R)-benzyl 2-hexyl-3-hydroxy-5-((triisopropylsilyl)oxy)hexadecanoate |
| ORLI-059 | 296242-38-1 | (2S,3S,5R)-2-hexyl-3-hydroxy-5-((triisopropylsilyl)oxy)hexadecanoic acid |
| ORLI-060 | 296242-39-2 | (3S,4S)-3-hexyl-4-((R)-2-((triisopropylsilyl)oxy)tridecyl)oxetan-2-one |
优化Route 4步骤 8 · 总收率 /
ORLI-019114264-05-0ORLI-020104872-06-2ORLI-0216113-61-7ORLI-06122348-97-6ORLI-06276062-97-0ORLI-063106265-08-1ORLI-064352557-26-7ORLI-065112764-00-8ORLI-066104801-96-9ORLI-067137433-01-3API · 奥利司他
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ORLI-019 | 114264-05-0 | (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyloxetan-2-one |
| ORLI-020 | 104872-06-2 | (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one |
| ORLI-021 | 6113-61-7 | (S)-2-formamido-4-methylpentanoic acid |
| ORLI-061 | 22348-97-6 | methyl 3-oxotetradecanoate |
| ORLI-062 | 76062-97-0 | methyl (R)-3-hydroxytetradecanoate |
| ORLI-063 | 106265-08-1 | 2-bromooctanoyl bromide |
| ORLI-064 | 352557-26-7 | (3R)-methyl 3-((2-bromooctanoyl)oxy)tetradecanoate |
| ORLI-065 | 112764-00-8 | (R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydro-2H-pyran-2-one |
| ORLI-066 | 104801-96-9 | (3S,4S,6R)-3-hexyl-4-hydroxy-6-undecyltetrahydro-2H-pyran-2-one |
| ORLI-067 | 137433-01-3 | (S)-1-phenylethanamine (2S,3S,5R)-5-(benzyloxy)-2-hexyl-3-hydroxyhexadecanoate |
优化Route 5步骤 11 · 总收率 17.30 mg
ORLI-020104872-06-2ORLI-0216113-61-7ORLI-030638-45-9ORLI-068112-54-9ORLI-0691066-54-2ORLI-070188349-76-0ORLI-071136022-04-3ORLI-072950194-37-3ORLI-07373501-38-9ORLI-0741376112-87-6ORLI-075274-07-7ORLI-076637741-97-0ORLI-07792144-04-2ORLI-0781376112-92-3ORLI-0791376112-94-5ORLI-080905910-48-7ORLI-081434935-69-0ORLI-082905910-49-8API · 奥利司他
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| ORLI-020 | 104872-06-2 | (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one |
| ORLI-021 | 6113-61-7 | (S)-2-formamido-4-methylpentanoic acid |
| ORLI-030 | 638-45-9 | 1-iodohexane |
| ORLI-068 | 112-54-9 | dodecanal |
| ORLI-069 | 1066-54-2在售 | ethynyltrimethylsilane |
| ORLI-070 | 188349-76-0 | 1-(trimethylsilyl)tetradec-1-yn-3-ol |
| ORLI-071 | 136022-04-3 | tetradec-1-yn-3-ol |
| ORLI-072 | 950194-37-3 | (S)-2-phenyl-2,3-dihydrobenzo[d]imidazo[2,1-b]thiazole |
| ORLI-073 | 73501-38-9 | (R)-tetradec-1-yn-3-ol |
| ORLI-074 | 1376112-87-6 | (R)-1-methoxy-4-((tetradec-1-yn-3-yloxy)methyl)benzene |
| ORLI-075 | 274-07-7 | benzo[d][1,3,2]dioxaborole |
| ORLI-076 | 637741-97-0 | (R)-3-((4-methoxybenzyl)oxy)tetradecanal |
| ORLI-077 | 92144-04-2 | ((1-(benzyloxy)vinyl)oxy)(tert-butyl)dimethylsilane |
| ORLI-078 | 1376112-92-3 | (3S,5R)-benzyl 3-hydroxy-5-((4-methoxybenzyl)oxy)hexadecanoate |
| ORLI-079 | 1376112-94-5 | (2S,3S,5R)-benzyl 2-hexyl-3-hydroxy-5-((4-methoxybenzyl)oxy)hexadecanoate |
| ORLI-080 | 905910-48-7 | (2S,3S,5R)-2-hexyl-3-hydroxy-5-((4-methoxybenzyl)oxy)hexadecanoic acid |
| ORLI-081 | 434935-69-0 | 2-methyl-6-nitrobenzoic anhydride |
| ORLI-082 | 905910-49-8 | (3S,4S)-3-hexyl-4-((R)-2-((4-methoxybenzyl)oxy)tridecyl)oxetan-2-one |
常见问题（FAQ）
奥利司他的适应症有哪些？
已批准的适应症包括：肥胖症。
奥利司他的专利什么时候到期？
奥利司他的专利到期年暂无公开口径，本页会在数据管道核实后更新。
奥利司他有几条合成路线？
本站收录 5 条合成路线，最短路线 8 步、总收率 /。每条路线的中间体均带登记编号与 CAS 号。
奥利司他的关键中间体在哪里可以采购？
奥利司他的多条路线中间体已挂接 CAS 档案，其中 3 个 CAS 已有优贝德（Unibest）供应网络在售报价，可在本页路线表中直接查看并询价。
如何获取奥利司他中间体的报价？
在本页选择目标中间体的 CAS 进入档案页，或在询价页直接提交需求；CAS 会自动带入供需撮合流程，由供应网络反馈报价。
数据来源：多源数据交叉核实（仅结构化字段） · 2026-09-27